Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate is ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

On February 9, 2026, Estrella Immunopharma, Inc. (NASDAQ:ESLA) announced that results from the Phase 1 Trial of CD19-ARTEMIS® T cells (EB103) in patients with aggressive B Cell Non-Hodgkin Lymphoma ...

) has been revised to $8.16 / share. This is a decrease of 50.00% from the prior estimate of $16.32 dated January 11, 2026. The price target is an average of many targets provided by analysts. The ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces the ...